NATCO Pharma has issued a clarification to the stock exchanges regarding a news article related to its Semaglutide product and partnership with Eris Lifesciences.
In its communication dated February 25, 2026 , the company stated that it had already disclosed the receipt of approval from the Central Drugs Standard Control Organisation for Semaglutide in India on February 14, 2026.
NATCO further informed that it is currently working with different marketing partners to launch the product in March 2026 in India. It clarified that the partnership for the said product with Eris Lifesciences Ltd is in the ordinary course of business and has no material impact on the operations of the company.
Responding to exchange queries on whether there was any undisclosed information that could explain the recent trading movement, the company replied in the negative. It also stated that, as of now, there is no material financial impact of the referenced article on the company.
NATCO added that it continues to comply with Regulation 30 of the SEBI (LODR) Regulations, 2015 and has been making consistent disclosures to the exchanges.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.